COMMUNIQUÉS West-GlobeNewswire

Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
14/08/2026
Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conference New clinical data for bizaxofusp, used for the treatment of unresectable recurrent IDH-WT [...]
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
14/08/2026
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regulatory pathway [...]
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
14/08/2026
The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA, including [...]
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
14/08/2026
- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed enrollment in the Phase 3 [...]
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
14/08/2026
- The transaction supports the evolution of the Company’s shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“ [...]
Milestone Scientific Reports Financial Results for Second Quarter 2026
14/08/2026
Medical Segment Revenue Grows 231% Year-Over-Year Enters Strategic Distribution Agreement to Expand CompuFlo® Access Across VA and Department of Defense Health Systems Reaffirms 2026 Outlook for Double-Digit Revenue [...]
Indiana Center for Recovery Named No. 1 Addiction Treatment Center in Indiana by Newsweek
14/08/2026
Indiana Center for Recovery in Bloomington ranks top in the state on Newsweek’s 2026 list for excellence in addiction treatment and mental health services. BLOOMINGTON, Ind., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Indiana [...]
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
14/08/2026
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD [...]
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
14/08/2026
TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to [...]
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
14/08/2026
Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections. Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients [...]
GT Biopharma Reports Second Quarter 2026 Financial Results
14/08/2026
Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to express B7-H3 initiated May 2026 [...]
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
14/08/2026
Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed Rezatapopt NDA submission for platinum-resistant/ [...]
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
14/08/2026
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP ® companion diagnostic into 2042 - AACR [...]
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
14/08/2026
COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and [...]
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
14/08/2026
NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
14/08/2026
Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2 2026 Net Loss [...]
TOMI Environmental Solutions, Inc. Reports Second Quarter 2026 Financial Results
14/08/2026
Company Delivers 118% Q2 Revenue Growth, Reaffirms Full-Year 2026 Guidance of $12 Million (113% YoY Growth) FREDERICK, Md., Aug. 14, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global [...]
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
14/08/2026
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-treated patients whose [...]
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
14/08/2026
Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the [...]

Pages